Healthcare
The medical imaging company has experienced a run for the ages, with the stock up 2,000% in the ASX in less than a year. Not everyone is convinced it can continue.
The Medical Research Future Fund can move money, but without matched capital and demand signals it will not build the companies Australia needs.
A “not financially material” contract with the influential Mayo Clinic triggered another surge in the medtech’s share price. Naysayers are starting to doubt themselves.
US-based Superpower is licensing Australian nasal spray technology from an ASX-listed biotech, and funding clinical research Big Pharma won’t touch.
The Australian weight-loss unicorn is being eaten up by a US company battling ongoing legal drama, a surge in short sellers, and a spiralling share price.
CEO Shrey Viranna said the Australia and New Zealand combined diagnostic imaging network’s IPO preparations provide “options” to its PE backer.
The Mayne Pharma vs Cosette takeover saga and ensuing legal battles have already reshaped Australian M&A. The latest, precedent-testing lawsuit could do so again.
